CYC Unaudited Trading Update - Preliminary FY2025 Results
Filed with ASX · · 3 pages · English
Cyclopharm Limited (ASX:CYC) provides the following unaudited trading update for the twelve months ended 31 December 2025 (FY2025). All figures remain subject to audit finalisation. FY2025 HIGHLIGHTS (UNAUDITED) • Record operating revenue of $32.3 million, representing 17% growth over FY2024. • Technegas® revenue of $16.7 million, up 10% year-on-year, with the United States now the Company’s large
In the deck
Earlier from Cyclopharm
- Trading Halt
- COPD Study Leveraging Technegas and AI-Driven Lung Analysis
- Technegas Recognised in Updated Clinical Guideline
- Insurer Indemnifies Cyclopharm
- Stanford Children's Health to Implement Technegas
Later from Cyclopharm
- Cyclopharm Successfully Completes A$14 million Placement
- Cyclopharm Capital Raising Investor Presentation
- Technegas Approved at the US National Institutes of Health
- Technegas US Footprint Expanding Across Four Regions
- Preliminary Final Report
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm